Immunological Variables Associated to ICI Toxicity in Cancer Patients

NCT05429866 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

441

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Melanoma
Non Small Cell Lung Cancer
Non-melanoma Skin Cancer
Gastrointestinal Cancer
Head and Neck Cancer
Renal Cell Carcinoma
Small Cell Lung Cancer
Mesothelioma, Malignant
Bladder Cancer
Merkel Cell Carcinoma
Hepatocellular Carcinoma
MSI-H Colorectal Cancer

Interventions

DRUG: Checkpoint Blockade, Immune

Sponsor

Jules Bordet Institute